Author:
Austin Bobbie Ann,Gadhia Ami D.
Publisher
Springer International Publishing
Reference12 articles.
1. Arrowsmith J Harrison R (2010) Drug repositioning: the business case and current strategies to repurpose shelved candidates and marketed drugs. In: Barrett MJ, Frail DE (eds) Drug repositioning: bringing new life to shelved assets and existing drugs. 2000, p 53, John Wiley & Sons, Inc., Hoboken, New Jersey
2. Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3:673–683
3. Barratt JM, Frail DE (2012) Drug repositioning: the business case and current strategies to repurpose shelved candidates and marketed drugs. In: Barrett MJ, Frail DE (ed) Drug repositioning: bringing new life to shelved assets and existing drugs. ISBN: 978–0–470-87827-9, Pg 2, Wiley
4. Cavalla D (2015) Gaming the system: the role of the pharmaceutical industry. In: Cavalla: off-label prescribing: justifying unapproved medicine. ISBN: 978–1–118-91207-2, Pg 66, Wiley-Blackwell
5. Department of health and human services food and drug administration: how to apply for designation as an Orphan product. 21 CFR Part 316 [Docket NO. 85N-0483], RIN 0905-AB55 Orphan drug regulations
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献